Table 1. Patient characteristics.
|
Patients (N=41)
|
||
|---|---|---|
| N | % | |
| Age (years) | ||
| Median | 58 | |
| Range | 40–75 | |
| ECOG performance status | ||
| 0 | 39 | 95 |
| 1 | 2 | 5 |
| 2 | 0 | 0 |
| Histology | ||
| Ductal infiltrating carcinoma | 37 | 90 |
| Lobular infiltrating carcinoma | 4 | 10 |
| ER expression (IHC) | ||
| Positive | 27 | 66 |
| Negative | 14 | 34 |
| HER-2 expression (IHC) | ||
| 3+ | 5 | 12 |
| Negative | 22 | 54 |
| Unknown | 14 | 34 |
| Prior adjuvant therapy | ||
| Yes | 30 | 73 |
| No | 11 | 27 |
| Prior adjuvant chemotherapy | 30 | 73 |
| Prior adjuvant anthracyclines | 22 | 54 |
| Prior adjuvant taxanes | 6 | 15 |
| Prior adjuvant hormonotherapy (tamoxifen) | 24 | 59 |
| Dominant sites of disease | ||
| Visceral | 34 | 83 |
| Soft tissue (lymph nodes and bone sites)a | 7 | 17 |
a
No patient had only bone metastases.